$YZJ Shipbldg SGD(BS6.SI)$      YZJ Shipbldg(BS6.SI) $3 above is the target price, once it's listed as a separate maritime entity from YZJ Financial.     To all existing YZJ Shipbldg retailer investor, seize this last opportunity to buy-in or hold-on this stock, so as to push up it's corporate shares buy-back price.     YZJ Shipbldg positive earnings Q4 YR2024 report, coupled with new FPU projects contract with BP, will soar it's stock price to new heights, by Q3-2025. 

$IX Biopharma(42C.SI)$ 0.8 Target Price. --Ix Biopharama Medical Breakthrough-- iX Biopharma achieved a major medical and commercial breakthrough with Wafermine, its patented sublingual (under-the-tongue) ketamine wafer for non-opioid acute pain management. --The Core Technology-- WaferiXFast Absorption: Wafers dissolve sublingually in minutes, letting active ingredients enter the bloodstream directly and bypass the gut. High Bioavailability: Provides a needle-free, predictable alternative to intravenous infusions or standard oral pills. Drug Repurposing: Applies the delivery system to central nervous system agents and other urgent indications. --Key Pipeline & Commercial Milestones-- Backed by a US$40.95 million contract from the US Departm

$Seatrium Ltd(5E2.SI)$ Bullish $3 above is the target price set by WallStreet & DBS analyst .   To all existing Seatrium retailer investor, seize this last opportunity to buy-in or hold-on till at least $2.5 buy-back price by Temasek Holdings is reached, so as to push up it's intrinsic shares value.    Seatrium positive earnings Q4 YR2024 report, coupled with recent rig expansion market in India and new FPU projects contract with BP, will soar it's stock price to new heights, in coming days [Call]  

$IX Biopharma(42C.SI)$ 0.8 Target Price. --iX Biopharma Ltd(42C) Growth Catalysts-- Shift towards commercialisation of WaferiX subligual delivery of drugs could bump up revenue by as much as 250% in FY-2026, backed by planned capacity expansion. Out-licensing of the sublingual ketamine wafer, Wafermine, for Phase 3 development will be a major catalyst and expected to turn iX Biopharma profitable in long-term. Specialty pharmaceutical and nutraceutical drugs will benefit from the planned six-fold increase in production capacity to meet the expected surge in demand. Investment Merits Out-licensing world's first sublingual ketamine formula, Wafermine, for Phase 3 development is a near-term catalyst. Since the completion of its end-of-Phase 2 meetin

$BigBear.ai Holdings(BBAI)$  $10 Target Price    Once Fed-Bank interest-rate cut, all AI-related stock like BBAI will upsurge to a bullish trend again.

$YZJ Shipbldg SGD(BS6.SI)$ 5% above current $2.5 support price set by various analysis.     To all existing YZJ retailer investor, hold-on till the $3 Target Price is reach, so as to push up it's intrinsic support value above $3.     YZJ  positive earnings Q4 YR2024 report, coupled with recent  multi-trillion Shipbuilding contracts, will soar it's stock price to new heights, in coming days [Call]  

$CNMC Goldmine(5TP.SI)$ 2 Target Price, in times of global trade and geopolitical tensions.  CNMC Goldmine's stock outlook for 2026 looks promising, with analysts predicting a potential upside. The current price is S$1.28, and some analysts have set a target price of S$2, implying a 12-month upside of around 70%. *Key Factors Influencing the Bullish Outlook:* - Gold Price: The company's performance is closely tied to gold

$Lithium Americas Corp.(LAC)$  $10 Target Price once Lithium market supply tighten by China's rare earth export restriction and Zimbabwe ban on Lithium export persist.  GM $650M investment on LAC valuation: GM's $650 million investment is a transformative event for LAC's valuation, acting as a catalyst that transitions the company's narrative from a high-risk explorer to a funded, strategically-aligned developer with secured future revenue. Its primary impact is not merely the addition of cash to the balance sheet, but the comprehensive de-risking of the entire Thacker Pass project. This de-risking—through secured funding, guaranteed offtake, and powerful strategic endorsement—justifies a higher valuation multipl

$CNMC Goldmine(5TP.SI)$ $ 2  Target Price by Q4-2025 due to U.S currency depreciation and upcoming Fed interest rate-cut.    According to the recent Q1 financial report, CNMC Goldmine posted a revenue of USD 52.8 million for the first half of 2025. The company's net income reached USD 19.42 million, with earnings per share (EPS) of USD 0.0389. Notably, the net income attributable to shareholders stood at USD 15.76 million, indicating a robust financial position and profitability for the gold miner.   CNMC Goldmine's positive financial results come at a time when the global gold market has been experiencing fluctuations due to various economic factors. The company's ability to maintain strong revenue and profitability in